Organovo Holdings, Inc. (ONVO)

USD 0.35

(-5.12%)

Market Cap (In USD)

5.37 Million

Revenue (In USD)

109 Thousand

Net Income (In USD)

-14.67 Million

Avg. Volume

92.37 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.32-1.74
PE
-
EPS
-
Beta Value
0.61
ISIN
US68620A2033
CUSIP
68620A203
CIK
1497253
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Keith E. Murphy
Employee Count
-
Website
https://www.organovo.com
Ipo Date
2012-02-14
Details
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. The company was incorporated in 2007 and is headquartered in Solana Beach, California.